NCT03543800

PRP Treatment of Osteoarthritic Knee With a New Autologous Blood Product (CytoRich)

Comparison of Conventional Platelet-Rich Plasma Treatment of Osteoarthritic Knee With a New Autologous Blood Product (CytoRich)

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Antnor · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

This study is aimed at evaluating the efficacy and safety of Cytorich compared to platelet-rich plasma (PRP) in alleviating pain and improving function in subjects with knee OA.

Detailed description

This active-controlled, randomized, double-blind, prospective study will enroll subjects with knee OA. Subjects will be randomized equally to treatment with 4 injections of ABP (test treatment) or 4 injections of PRP (active control).

Conditions

• Osteoarthritis of the Knee

Interventions

Type	Name	Description
DEVICE	Cytorich PRP kit	Subjects randomized to the PRP treatment arm will receive PRP only without the anti-inflammatory component of ABP added
DEVICE	PRP kit	PRP kit legally marketed in Canada for PRP

Timeline

• Start date: 2015-02-04
• Primary completion: 2019-05-20
• Completion: 2019-05-20
• First posted: 2018-06-01
• Last updated: 2018-06-01

Locations

1 site across 1 country: Canada